Den amerikanske medicinalkoncern Eli Lilly, der blandt andet konkurrerer med Novo Nordisk på området for behandling af diabetes og af fedme, har mandag besluttet sig for at hæve sit kvartalsudbytte med 15 pct. til 1,13 dollar per aktie.
Det fremgår af en meddelelse.
Udbetalingen af udbytte på 1,13 dollar per aktie vil ske første gang i regnskabsåret 2022/23's første kvartal.
Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.
Medical Writer
QA Project Manager - ensure high-quality health care products
Regulatory Affairs Associate
Senior Quality Specialist Business Support Team, Medical Devices, Ferrosan
Senior Test Engineer
Design Control Specialist - ensure safe, high-quality products
.jpg&w=384&q=75)
Senior Regulatory Affairs Manager
Experienced Bioanalytical Scientist
Senior/Principal Scientist Pharmacology & Biology, Synklino
Senior Process Engineer with Project Experience
Test Engineer
Senior Scientist, Analytical Development
Regulatory Affairs Specialist
Team Manager, Analytical Chemistry
Manager of Quality Assurance Operation Support Team, Medical Devices, Ferrosan Medical Devices
Endpoint Engineer
Chief Commercial Officer
IT Infrastructure Engineer
Experienced Scientist, Oncology Research
Senior/Principal CMC Development Scientist, Synklino
Akademisk medarbejder til Environmental Monitoring – Aseptisk Produktion
Senior Principle Project Portfolio Manager
